CagriSema: What to Know About Novo Nordisk’s Next Weight Loss Drug

If you follow GLP-1 medication news, you have probably started hearing about CagriSema. It is Novo Nordisk's next-generation weight loss drug, and the clinical trial data is some of the most impressive in obesity research to date: more than 20 percent average weight loss, with 60 percent of participants losing 20 percent or more of their body weight. Those numbers are significantly better than what semaglutide (Wegovy/Ozempic) achieves on its own.

I have been following CagriSema's development closely as part of my ongoing research into the GLP-1 medication landscape. The drug is not yet approved and is not yet available, but Novo Nordisk filed for FDA approval in December 2025, and a decision is expected in late 2026. This guide covers everything we know so far, including the clinical trial data, how it differs from current GLP-1 medications, the side effect profile, and what it could mean for women who are currently using or considering weight management medications.

Disclaimer: Links may contain affiliate links, which means we may get paid a commission at no additional cost to you if you purchase through this page. Read our full disclosure here.

What Is CagriSema?

CagriSema is a fixed-dose combination of two medications in a single once-weekly injection: cagrilintide (2.4 mg), a long-acting amylin analog, and semaglutide (2.4 mg), the same GLP-1 receptor agonist found in Wegovy and Ozempic. If approved, it would be the first injectable combination of a GLP-1 and an amylin analog on the market.

The idea behind CagriSema is straightforward: semaglutide alone produces significant weight loss (typically 15 to 17 percent), but adding cagrilintide targets a second appetite regulation pathway through the amylin system. The combination addresses two distinct hormonal mechanisms simultaneously, which is why the weight loss results exceed what either drug achieves individually.

How CagriSema Works: Two Hormones, One Injection

To understand why CagriSema is significant, it helps to understand the two hormonal systems it targets.

Semaglutide activates GLP-1 receptors in the brain and gut. This reduces appetite, increases feelings of fullness after eating, and slows gastric emptying (the rate at which food leaves your stomach). If you have read my guide to how GLP-1 works, this mechanism will be familiar.

Semaglutide has been on the U.S. market since FDA approval in December 2017 and is supported by extensive clinical data across major trial programs, including SUSTAIN (over 8,000 patients) and PIONEER (more than 9,500 patients). Separately, Reuters reported that Novo Nordisk sold around 3.2 million combined U.S. prescriptions of Wegovy and Ozempic in the four weeks between September 27 and October 25, 2024.

Cagrilintide is the newer component. It is a long-acting analog of amylin, a peptide hormone that is co-secreted with insulin from pancreatic beta cells after eating. Amylin works through different brain regions than GLP-1, particularly the area postrema and hindbrain, to enhance satiety signaling and suppress glucagon. Natural amylin, like natural GLP-1, is broken down quickly. Cagrilintide is engineered to last much longer, providing sustained activation of the amylin pathway.

The researchers behind CagriSema said the combination may work through complementary effects on appetite regulation in brain regions involved in both hedonic and homeostatic appetite regulation. In simpler terms: semaglutide and cagrilintide reduce hunger and increase fullness through different mechanisms, and the effects appear to be additive rather than redundant.

REDEFINE 1 Trial Results: Obesity Without Diabetes

The REDEFINE 1 trial, published in The New England Journal of Medicine in June 2025, is the primary study supporting CagriSema's FDA application. Here is what the data showed.

The trial enrolled 3,417 adults without diabetes who had obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related health condition. Participants were randomized to receive CagriSema, semaglutide alone, cagrilintide alone, or placebo, all alongside lifestyle interventions for 68 weeks.

The headline results: participants on CagriSema lost an average of 20.4 percent of their body weight, compared to 14.9 percent with semaglutide alone, 11.5 percent with cagrilintide alone, and 3.0 percent with placebo. When looking only at participants who adhered to treatment for the full 68 weeks, average weight loss with CagriSema reached 22.7 percent.

To put those numbers in context, a 200-pound woman on CagriSema who stuck with treatment for the full duration could expect to lose roughly 45 pounds. That exceeds what semaglutide alone typically achieves by a meaningful margin.

The weight loss thresholds tell an even more compelling story. Among participants analyzed under the trial’s adherence-based estimate, 40.4 percent achieved at least 25 percent weight loss and 23.1 percent achieved at least 30 percent weight loss. Those are among the strongest categorical weight-loss results reported to date in a late-stage pharmaceutical obesity trial.

Beyond weight, CagriSema also produced significant improvements in systolic blood pressure and waist circumference, with additional improvements observed in lipid levels and glycemic markers. Among participants with prediabetes at baseline, 87.7 percent attained normal blood glucose levels, compared with 32.2 percent on placebo. That finding is especially notable because it suggests potential metabolic benefits beyond weight loss alone.

REDEFINE 2 Trial Results: Obesity With Type 2 Diabetes

The REDEFINE 2 trial, also published in The New England Journal of Medicine, evaluated CagriSema in 1,206 adults who had both type 2 diabetes and overweight or obesity. This is a harder population to treat because diabetes complicates weight loss through insulin resistance, medication effects, and metabolic adaptation.

Even in adults with type 2 diabetes, CagriSema delivered 13.7 percent average weight loss regardless of adherence, versus 3.4 percent with placebo; with full treatment adherence, weight loss reached 15.7 percent. It also substantially improved glycemic control, with 73.5 percent of participants reaching an HbA1c of 6.5 percent or less, compared with 15.9 percent on placebo.

Side Effects and Safety Profile

The side effect profile of CagriSema is consistent with what has been observed across GLP-1 medications, with gastrointestinal issues being the most common.

In REDEFINE 1, gastrointestinal adverse events were reported in 79.6 percent of participants on CagriSema compared with 39.9 percent on placebo. The most common were nausea, diarrhea, vomiting and constipation. Most were mild to moderate in severity and nausea, diarrhea and vomiting were most common during dose escalation before declining over time. Discontinuation due to adverse events was still relatively uncommon, but it was higher with CagriSema than placebo: 5.9 percent versus 3.5 percent.

The GI side effect rates are higher than what is typically seen with semaglutide alone (around 74 percent in OASIS 4), which makes sense given that CagriSema combines two appetite-suppressing mechanisms. However, the fact that discontinuation rates remained low suggests that most patients can tolerate the side effects with proper dose escalation and management.

For strategies on managing GI side effects, including dietary approaches that help, read my guide to Ozempic side effects for women. The same management strategies (eating slowly, choosing easy-to-digest foods, staying hydrated, protein-first eating) apply to CagriSema.

How CagriSema Compares to Current Medications

Here is how CagriSema's weight loss results compare to the current FDA-approved options, based on their respective pivotal trials. Note that these are cross-trial comparisons (different study populations and protocols), not head-to-head data, so they should be interpreted as general context rather than direct rankings.

Semaglutide 2.4 mg injection (Wegovy) produced roughly 15 to 17 percent weight loss in the STEP trials. Oral semaglutide 25 mg (the Wegovy pill) produced about 14 to 17 percent in OASIS 4. Tirzepatide (Zepbound/Mounjaro) produced roughly 21 to 23 percent in the SURMOUNT trials at the highest dose. CagriSema produced 20 to 23 percent in REDEFINE 1.

Novo Nordisk ran a head-to-head trial (REDEFINE 4) comparing CagriSema directly to tirzepatide at 84 weeks. Results released in February 2026 showed CagriSema produced slightly less weight loss than tirzepatide, falling short of the superiority it was hoping to demonstrate. However, at roughly 23 percent weight loss, CagriSema still produced clinically meaningful results that exceed semaglutide alone.

For women who are currently on Wegovy or Ozempic and wondering whether CagriSema would be worth switching to, the honest answer is: we will not know until it is approved and real-world data emerges. The incremental weight loss benefit over semaglutide alone (roughly five to six additional percentage points) is meaningful, but the decision will also depend on cost, insurance coverage, side effect tolerance, and individual response.

FDA Approval Timeline

Novo Nordisk submitted a New Drug Application (NDA) to the FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 trial data. The FDA is expected to review the application in 2026.

Under a standard FDA review timeline (10 to 12 months), approval would come in late 2026 or early 2027. If CagriSema receives priority review (which is possible given its efficacy profile), the timeline could accelerate to late 2026. The PDUFA date (the FDA's target decision deadline) will likely be set in Q2 2026 after the NDA is accepted for filing.

Novo Nordisk has indicated that manufacturing is underway and it is prepared for commercial launch following approval. However, the real-world availability will depend on production capacity and the rollout strategy. Based on the Wegovy pill launch experience, it is reasonable to expect that supply may be limited initially.

No official pricing has been announced, but analysts project CagriSema will be priced at or above Wegovy's current list price, likely in the $1,300 to $1,500 per month range. Insurance coverage will be a significant factor in accessibility.

Novo Nordisk is also planning a Phase 3 trial of a high-dose version of CagriSema (2.4 mg cagrilintide / 7.2 mg semaglutide) starting in the second half of 2026. If the higher semaglutide dose follows the same pattern seen with high-dose Wegovy (which increased weight loss from roughly 16 to 21 percent), the high-dose CagriSema results could be even more substantial.

What This Means for Current GLP-1 Users

If you are currently on a GLP-1 medication and wondering how CagriSema fits into the picture, here is my take.

If you are doing well on your current medication, there is no reason to wait for CagriSema or to stop what is working. The best medication is the one that produces results you can sustain with a side effect profile you can tolerate. CagriSema will be an additional option, not a replacement for everything that came before it.

If you have plateaued on semaglutide or are not getting the results you hoped for, CagriSema's dual mechanism could potentially offer additional benefit. But it is not available yet, and it may take months after approval before it is widely accessible.

Regardless of which medication you use or whether CagriSema becomes part of your treatment plan in the future, the nutrition and exercise foundation remains the same. Protein-first eating, resistance training and body composition awareness are what protect your lean mass, your metabolism and your long-term results. The medication is the accelerator. The lifestyle habits are the engine.

For that foundation, start with the GLP-1 diet plan, use the protein calculator for women to find your daily target, and check out the GLP-1 workout plan for structured training programs.

This article was last updated April 6, 2026. CagriSema is an investigational drug not yet approved by the FDA. I will update this article when the FDA announces a PDUFA date, when approval decisions are made, and when pricing or availability information becomes available.